Antitumor Activity with CYP17 Blockade Indicates That Castration-Resistant Prostate Cancer Frequently Remains Hormone Driven

被引：140

作者：

Attard, Gerhardt ^{[1
]}

Reid, Alison H. M. ^{[1
]}

Olmos, David ^{[1
]}

de Bono, Johann S. ^{[1
]}

机构：

[1] Royal Marsden NHS Fdn Trust, Inst Canc Res, Med Sect, Sutton SM2 5PT, Surrey, England

来源：

CANCER RESEARCH | 2009年 / 69卷 / 12期

基金：

英国医学研究理事会;

关键词：

ANDROGEN RECEPTOR; ANTIANDROGEN WITHDRAWAL; ABIRATERONE ACETATE; KETOCONAZOLE; INHIBITOR; MECHANISM; THERAPY; GROWTH; GENES; CELLS;

D O I：

10.1158/0008-5472.CAN-08-4531

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Abiraterone acetate is a potent, selective, and orally bioavailable small molecule inhibitor of CYP17, an enzyme that catalyzes two key serial reactions (17 alpha hydroxylase and 17,20 lyase) in androgen and estrogen biosynthesis. Clinical trials have confirmed that specific inhibition of CYP17 is safe and results in clinically important antitumor activity in up to 70% of castrate patients with advanced prostate cancer resistant to currently available endocrine therapies. These clinical data indicate that castration-resistant prostate cancer frequently remains hormone dependent and has confirmed that this disease should no longer be described as "hormone resistant or refractory". Biomarker studies, including the analysis of ETS gene fusion status, on patients treated with abiraterone acetate may allow enrichment of patients with a sensitive phenotype in future studies of therapeutics targeting CYP17. [Cancer Res 2009;69(12):4937-40]

引用

页码：4937 / 4940

页数：4

共 20 条

[1] Dissecting prostate carcinogenesis through ETS gene rearrangement studies:: implications for anticancer drug development [J].

Attard, G. ;

Ang, J. E. ;

Olmos, D. ;

de Bono, J. S. .

JOURNAL OF CLINICAL PATHOLOGY, 2008, 61 (08) :891-896

[2] Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven [J].

Attard, Gerhardt ;

Reid, Alison H. M. ;

Yap, Timothy A. ;

Raynaud, Florence ;

Dowsett, Mitch ;

Settatree, Sarah ;

Barrett, Mary ;

Parker, Christopher ;

Martins, Vanessa ;

Folkerd, Elizabeth ;

Clark, Jeremy ;

Cooper, Colin S. ;

Kaye, Stan B. ;

Dearnaley, David ;

Lee, Gloria ;

de Bono, Johann S. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) :4563-4571

[3] Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer [J].

Attard, Gerhardt ;

Swermenhuis, Joost F. ;

Olmos, David ;

Reid, Alison H. M. ;

Vickers, Elaine ;

A'Hern, Roger ;

Levink, Rianne ;

Coumans, Frank ;

Moreira, Joana ;

Riisnaes, Ruth ;

Oommen, Nikhil Babu ;

Hawche, George ;

Jameson, Charles ;

Thompson, Emilda ;

Sipkema, Ronald ;

Carden, Craig P. ;

Parker, Christopher ;

Dearnaley, David ;

Kaye, Stan B. ;

Cooper, Colin S. ;

Molina, Arturo ;

Cox, Michael E. ;

Terstappen, Leon W. M. M. ;

de Bono, Johann S. .

CANCER RESEARCH, 2009, 69 (07) :2912-2918

[4] The genetics, pathophysiology, and management of human deficiencies of P450c17 [J].

Auchus, RJ .

ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2001, 30 (01) :101-+

[5] PHARMACOLOGY OF NOVEL STEROIDAL INHIBITORS OF CYTOCHROME P450(17-ALPHA) (17-ALPHA-HYDROXYLASE C17-20 LYASE) [J].

BARRIE, SE ;

POTTER, GA ;

GODDARD, PM ;

HAYNES, BP ;

DOWSETT, M ;

JARMAN, M .

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1994, 50 (5-6) :267-273

[6] Molecular determinants of resistance to antiandrogen therapy [J].

Chen, CD ;

Welsbie, DS ;

Tran, C ;

Baek, SH ;

Chen, R ;

Vessella, R ;

Rosenfeld, MG ;

Sawyers, CL .

NATURE MEDICINE, 2004, 10 (01) :33-39

[7] A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase [J].

Craft, N ;

Shostak, Y ;

Carey, M ;

Sawyers, CL .

NATURE MEDICINE, 1999, 5 (03) :280-285

[8] Pregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptor [J].

Grigoryev, DN ;

Long, BJ ;

Njar, VCO ;

Brodie, AHM .

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2000, 75 (01) :1-10

[9] The current state of hormonal therapy for prostate cancer [J].

Hellerstedt, BA ;

Pienta, KJ .

CA-A CANCER JOURNAL FOR CLINICIANS, 2002, 52 (03) :154-179

[10] Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer [J].

Hu, Rong ;

Dunn, Thomas A. ;

Wei, Shuanzeng ;

Isharwal, Sumit ;

Veltri, Robert W. ;

Humphreys, Elizabeth ;

Han, Misop ;

Partin, Alan W. ;

Vessella, Robert L. ;

Isaacs, William B. ;

Bova, G. Steven ;

Luo, Jun .

CANCER RESEARCH, 2009, 69 (01) :16-22

← 1 2 →